Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 314338
Institute Patents means any and all Patents Controlled by Institute or its Affiliate(s) as of the Effective Date or thereafter during the Term that (i) claim the composition of matter of, or the method of manufacturing or using, any Compound or Product; or (ii) that otherwise relate to, or are reasonably necessary for, the use, development, manufacture or commercialization of any Compound or Product, including the Patents set forth.
7,754,764 – Fatty acid nutritional supplement
7,705,048 – Method of suppressing the effects of the translocase deficiency of a human infant comprising administration of a seven-carbon fatty acid
7,592,370 – Fatty acid treatment for cardiac patients
Product means any nutritional or pharmaceutical product, including all dosage forms and formulations, containing one or more Compound(s) as an Active Ingredient(s) (alone or as part of a Combination Product). Except when referred to in the Net Sales definition in describing how to calculate the Net Sales of Combination Products, all references to Product in this Agreement shall be deemed to include Combination Products. Two Products shall be deemed the same Product if they contain the same Compound as the Active Ingredient.
Patents means all patents and patent applications and any patents issuing therefrom (which for the purpose of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions, continuations-in-part, converted provisionals, continued prosecution applications, adjustments, re-examinations, reissues, additions, renewals, revalidations, extensions (including patent term extensions, and supplemental certificates and the like), registrations, pediatric exclusivity periods of any such patents and patent applications, and any and all foreign equivalents of the foregoing.
Institute is a research center focused on finding prevention therapies and treatments for diseases and illnesses.
Adult polyglucosan body disease (APBD) is a rare, genetic disorder characterized by a deficiency of glycogen-branching enzyme, resulting in the accumulation of polyglucosan bodies in muscle, nerve and various other tissues of the body. Polyglucosan bodies are composed of large, complex, sugar-based molecules.
Adult polyglucosan body disease (APBD) is an orphan disease and a glycogen storage disorder that is caused by an inborn error of metabolism. Symptoms can emerge any time after the age of 30; early symptoms include trouble controlling urination, trouble walking, and lack of sensation in the legs. People eventually develop dementia.
Licensee is a biotechnology company focused on the discovery and development of innovative therapeutics for patients with rare and ultra-rare genetic diseases.
IPSCIO Record ID: 279355
License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.
Collaboration Compound shall mean a Licensor Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensee Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC. A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensor or Licensee or their Affiliates to protect any compound in category (i), (ii) or (iii) above. A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above. For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensee Compound, Licensor Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound. Joint Research Committee or â€œJRCâ€ shall mean the entity organized to manage the scientific implementation of the Collaboration.
Licensee IP shall mean Licensee Patents and Licensee Know-how.
Collaboration IP shall mean Collaboration Patents and Collaboration Know-how. Collaboration IP shall not include Licensor IP or Licensee IP.
Licensor IP shall mean Licensor Patents and Licensor Know-how. Licensor IP shall not include any intellectual property owned or licensed by Licensor or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).
Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the effective date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the Effective Date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensee, Licensor or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensor or Licensee during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensee Patents or Licensor Patents.
Licensor Compound shall mean any compound brought to the Collaboration by Licensor, which is Controlled by Licensor at or after the Effective Date, and which is proprietary to Licensor by virtue of being within the Licensor IP.
Licensor Field shall mean, with respect to each Collaboration Compound for which Licensor has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
Licensee Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
IPSCIO Record ID: 331383
Licensor Know-How means all unpatented inventions, technology, methods, materials, including biological and pharmaceutical materials, know-how, studies, pre-clinical and clinical data, including toxicology, safety data, and bioequivalence studies, tests and assays, reports, manufacturing processes, including manufacturing batch records to support regulatory approvals, regulatory filings and approvals and other information owned or licensed by Licensor as of the Effective Date with the right to license or sublicense without violating the terms of any agreement to which Licensor is party, in each case that relates to Axxx-001 or the subject matter claimed by Licensor Patents or Licensor controlled Patents.
Licensor patents are
Palatable comositions including Sodium Phenylbutyrate and uses thereof, and,
Administration of Sodium Phenylbutyrate in a fasted state to treat urea cycle disorders.
Licensor controlled patent is Methods of modulation of branched chain acids and uses thereof.
Urea cycle disorder (UCD) is an inherited disease that affects how the body removes the waste that is made from breaking down protein. Everyone needs protein, which is found in foods like dairy products, meat and fish.
Infants with a urea cycle disorder appear normal at birth but rapidly develop cerebral edema and the related signs of lethargy, anorexia, hyper- or hypoventilation, hypothermia, seizures, neurologic posturing, and coma.
Classical Maple Syrup Urine Disease (MSUD) is a disease of infancy which is an inherited disorder of metabolism of branched-chain amino acids (BCAA).
Maple syrup urine disease (MSUD) is an autosomal recessive metabolic disorder affecting branched-chain amino acids. It is one type of organic acidemia. The condition gets its name from the distinctive sweet odor of affected infants' urine, particularly prior to diagnosis and during times of acute illness.
IPSCIO Record ID: 334760
An exclusive, even as to Licensor, worldwide, assignable, transferable sublicense, including the right to sublicense through multiple tiers of sublicense, to Institutionsâ€™ IP to make, have made, use, import, offer to sell, sell and have sold, copy, modify, perform, display, create derivative versions of Products in the Field or otherwise to exploit the Institutionsâ€™ IP in the Field to any lawful purpose.
EP 16382660.5 – Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof;
EP 16382672.0 – Heteroaryl compounds and their use in the treatment of gaucherâ€™s disease;
PCT/EP2014/066392 – Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof; and,
EP15382019.6 – Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
The Institutionsâ€™ IP and Licensorâ€™s IP are hereinafter jointly referred to as the Technology.
— Institutionsâ€™ IP shall mean
(i) the patent no. EP 11380102 titled Method Of Binding Site And Binding Energy Determination By Mixed Explicit Solvent Simulations; (ii) any divisionals, substitutions, continuations and continuations-in part of the foregoing patent (excluding claims of the foregoing that is not entitled to the priority date of patent); (iii) all reissues, reexaminations, extensions, registrations, patent term extensions and restorations, supplementary protection certificates and renewals of any of the foregoing patent; and (iv) the Intellectual Property rights in connection thereto, including the corresponding know-how and software; in each case, anywhere in the world.
— Licensorâ€™s IP shall mean (i) the Site-Directed Enzyme Enhancement Therapy (SEE-TXÂ®) discovery platform for identification of non-competitive pharmacological chaperones, (ii) Licensorâ€™s Molecules acting as pharmacological chaperones, (iii) Licensorâ€™s Know-How and (iv) Licensorâ€™s Trademark named SEE-Tx including all methods, data sets, technical documents pertaining to the screening technology including specification, diagrams, lab results, any and all notes, all inventor notebook pages specific to the program, all patents, pending, issued, or filed to the screening technology.
IPSCIO Record ID: 371629
Friedreich's ataxia is an inherited disorder that affects some of the body's nerves. It is caused by a gene defect that is inherited from both parents. Symptoms often begin in late childhood and can include trouble walking, fatigue, changes in sensation, and slowed speech. These tend to get worse over time.
IPSCIO Record ID: 342806
For the Research and Manufacturing License in the Territory, Licensor grants a non-exclusive license, with the right to sublicense, under the Licensor Patents that cover the Territory and Licensor Know-How and Licensors rights under the Joint Inventions and Joint Patents, to research, develop and manufacture the Licensed Molecules and Products in the Territory solely for the purpose of advancing the research, development and commercialization of the Licensed Molecules and Products outside the Territory.
Product shall mean a pharmaceutical product containing at least one Licensed Molecule, including all dosage forms, formulations, line extensions and modes of administration thereof.
The related patents include
– Amino substituted diary [a,d.] Cycloheptene analogs as muscarinic agonists and methods of treatment of Neuropsychiatric disorders,
– Use of N-Desmethylclozapine and related compounds as dopamine stabilizing agents, and,
– Prodrugs of muscarinic agonists and methods of treatment of Neuropsychiatric disorders.